Eisai latest cancer drugmaker to win UK approval after price cut

LONDON (Reuters) - Cancer drugmakers are cutting prices to ensure their medicines are used routinely on Britain's National Health Service, following the overhaul of a cancer drug funding scheme, with Japan's Eisai the latest to win approval.